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Purpose: The deleted in bladder cancer 1 (DBC1) gene is located within chromosome 
9 (9q32-33), a chromosomal region that frequently shows loss of heterozygosity in blad-
der cancer (BC). It is suspected that it acts as a tumor suppressor gene, but its prognostic 
value remains unclear. The aim of the present study was to investigate the value of 
DBC1 as a prognostic marker in BC.
Materials and Methods: The expression of DBC1 was determined by real-time polymer-
ase chain reaction analysis in 344 patients with BC (220 non-muscle-invasive BC 
[NMIBC] and 124 muscle-invasive BC [MIBC]) and in 34 patients with normal bladder 
mucosa. The results were compared with clinicopathologic parameters, and the prog-
nostic value of DBC1 was evaluated by Kaplan-Meier analysis and a multivariate Cox 
regression model. 
Results: DBC1 expression was significantly decreased in patients with MIBC compared 
with those diagnosed with NMIBC (p=0.010). Patients with aggressive tumor charac-
teristics had lower DBC1 expression levels in NMIBC (each, p＜0.05). By multivariate 
Cox regression analysis, low DBC1 expression was a predictor of progression to MIBC 
(hazard ratio, 7.104; p=0.013). Kaplan-Meier estimates revealed a significant differ-
ence in tumor recurrence, progression to MIBC, and cancer-specific survival depending 
on the level of DBC1 expression in NMIBC (log-rank test, each, p＜0.05). 
Conclusions: The expression of DBC1 was associated with tumor aggressiveness, pro-
gression to MIBC, and survival in NMIBC. Our results suggest that DBC1 expression 
can be a useful prognostic marker for patients with NMIBC.
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INTRODUCTION 
Bladder cancer is the second most common genitourinary 
tumor in human populations, and it was estimated in 2013 
that 72,570 new cases of cancer of the urinary bladder were 
diagnosed in the United States and 15,210 deaths were at-
tributable to bladder cancer [1]. At the initial diagnosis, 
75% of patients present with non-muscle-invasive bladder 
cancer (NMIBC), which can be managed with a combina-
tion of transurethral resection (TUR) and intravesical 
therapy [2,3]. However, after TUR about three-quarters of 
patients experience tumor recurrence within 2 years, and 
20% to 30% of them experience progression to muscle-in-
vasive bladder cancer (MIBC) [4,5]. Only 20% of bladder Korean J Urol 2013;54:631-637
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cancer patients are diagnosed with MIBC, which causes 
most cancer-specific deaths. Although radical cystectomy 
is considered the gold standard for the treatment of pa-
tients with localized MIBC, about 50% of these patients de-
velop metastases within 2 years after cystectomy and sub-
sequently die of the disease [6].
Bladder cancer has diverse biological and functional 
characteristics. Therefore, it is very difficult for urologists 
to estimate the success rate of treatment and to counsel pa-
tients about prognosis [7]. Prognostic information ob-
tained from conventional histopathological parameters 
such as tumor stage or grade and lymph node status is insuf
ﬁcient to predict outcome. One limitation of the current use 
of staging is the fact that tumors of a similar stage and grade 
can have a significantly different biology [8]. Nomograms 
and prognostic modeling approaches that simultaneously 
incorporate many factors have been developed for assess-
ing the risk of individual patients [3,9,10]. The limited val-
ue of the established prognostic markers is that these re-
quire analysis of new molecular parameters of interest for 
predicting the prognosis of bladder cancer patients in a 
clinical setting [11]. The specific alterations in gene ex-
pression that occur as a result of the cross-talk between var-
ious cellular pathways determine the biological behavior 
of a tumor, including its growth, recurrence, progression, 
and metastasis, all of which can influence patient survival 
[7,11-14]. To detect and monitor cancer and determine a 
likely prognosis, it is necessary to identify molecular mark-
ers of the disease that can be used in a clinic.
The deleted in bladder cancer 1 (DBC1) gene, originally 
named DBCCR1, which represents a candidate tumor sup-
pressor gene within a precisely mapped region of loss of het-
erozygosity on 9q33, shows the loss of one allele in 60% of 
all bladder tumors or transcriptional silencing in approx-
imately 50% of bladder cancer cell lines by promoter hyper-
methylation of the 5’ region of DBC1 containing a CpG is-
land [15-18]. Abnormal methylation or deletion of DBC1 
has also been described in other tumors including oral squ-
amous cell carcinoma, non-small-cell lung cancer, and 
acute lymphoblastic leukemia [19,20]. DBC1 contains a 
membrane attack complex/perforin domain, which is a 
membrane-disrupting protein that is involved in pore for-
mation during complement-mediated cell lysis [16]. DBC1 
is also known to play a role in cell cycle control. Exogenous 
expression of DBC1 protein in human bladder tumor cell 
lines results in suppression of proliferation, and this 
DBC1-mediated growth inhibition is due to an increase in 
the number of cells in the G1 phase of the cell cycle [16,21]. 
Thus far, there has been no evidence for an equivalent func-
tion of DBC1, and clinical evidence is insufficient as to 
whether the inactivation of the DBC1 tumor suppressor 
gene influences genetic susceptibility and the disease 
course of bladder cancer. 
In the current study, we compared the expression levels 
of DBC1 between normal and cancer tissue to assess the 
contribution of this gene in bladder carcinogenesis. More 
importantly, we assessed the value of DBC1 as a prognostic 
indicator for bladder cancer.
MATERIALS AND METHODS
1. Study population
We collected bladder tissue from 344 patients with primary 
bladder cancer (220 NMIBC and 124 MIBC) and 34 pa-
tients with nonmalignant, noninflammatory disease. 
Cases were recruited from patients with bladder cancer 
who had been histologically verified with urothelial carci-
noma at our institution. To reduce confounding factors af-
fecting the analysis and to delineate a more homogeneous 
study population, any patients diagnosed with a con-
comitant carcinoma in situ, or for whom data collection was 
incomplete, as well as patients with short-term follow-up 
periods (less than 6 months) were excluded. The Ethics 
Committee of Chungbuk National University approved 
this protocol, and written informed consent was obtained 
from each subject. The collection and analyses of all sam-
ples was approved by the Institutional Review Board of 
Chungbuk National University (IRB approval number 
2006-01-001), and informed consent was obtained from 
each subject.
Tumors were staged according to the 2002 TNM classi-
fication and the 1973 World Health Organization grading 
system [22]. All diagnoses were confirmed by pathological 
analysis of frozen sections from cystectomy and TUR 
specimens. In the case of NMIBC, a TUR of the tumor was 
performed. A second TUR was performed 2 to 4 weeks after 
the initial resection when a bladder cancer specimen did 
not include proper muscle or when a high-grade tumor was 
detected. Patients who had multiple tumors, large tumors 
(≥3 cm in diameter), or high-grade NMIBC received one 
cycle of intravesical treatment (bacille Calmette-Guerin 
[BCG] or mitomycin-C). Response to treatment was as-
sessed by cystoscopy and urinary cytology. Patients who 
were free of disease within 3 months of the commencement 
of treatment were assessed every 3 months for the first 2 
years and every 6 months thereafter [5]. We defined re-
currence as a relapse of primary NMIBC with a lower or 
equivalent pathologic stage and progression to invasive 
bladder cancer. 
2. RNA extraction and construction of cDNA 
One milliliter of TRIzol (Invitrogen, Carlsbad, CA, USA) 
was added to control and bladder cancer tissue and the sam-
ples were homogenized in a 5-mL glass tube. The homoge-
nate was transferred to a 1.5-mL tube and was mixed with 
200 μL chloroform. After incubation for 5 minutes at 4
oC, 
the homogenate was centrifuged for 13 minutes at 13,000× 
g at 4
oC. The upper aqueous phase was transferred to a 
clean tube and 500 μL isopropanol was added, followed by 
incubation for 60 minutes at 4
oC. The tube was then centri-
fuged for 8 minutes at 13,000×g and 4
oC. Then, the upper 
aqueous phase was removed, mixed with 500 μL of 75% 
ethanol, and centrifuged for 5 minutes at 13,000×g and 4
oC. 
After the upper aqueous layer was discarded, the pellet was Korean J Urol 2013;54:631-637
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TABLE 1. Baseline characteristics
Characteristic Controls (n=34) NMIBC (n=220)  MIBC (n=124)
Age (yr), mean±SD (range) 
Follow-up period (mo), median (range) 
DBC1 mRNA expression level (×10
4 copies per 
μg), median (IQR)
a
Gender, n (%)
    Male 
    Female 
Grade, n (%)
    G1 
    G2 
    G3 
TNM stage, n (%)
    TaN0M0
    T1N0M0 
    T2N0M0 
    T3N0M0
    T4 or higher than N0M0
53.85±14.5 (19–80)
-
17.49 (9.84–36.12)
18 (52.9)
16 (47.1)
-
-
-
-
-
-
-
66.1±13.8 (24–87)
62.0 (6.0–220.0)
  36.55 (6.38–109.02)
182 (82.7)
  38 (17.2)
  72 (32.7)
118 (53.6)
  30 (13.6)
  84 (38.2)
136 (61.8)
67.34±9.4 (38–87)
35.0 (6.0–181)
   17.32 (3.87–63.23)
103 (83.1)
  21 (16.9)
  37 (29.8)
  85 (68.5)
  60 (48.4)
  34 (27.4)
  30 (24.2)
NMIBC, nonmuscle invasive bladder cancer; MIBC, muscle invasive bladder cancer; SD, standard deviation; IQR, interquartile range.
a:p＜0.05 between NMIBC and MIBC, p-values was based on the Mann-Whitney U test.
dried at room temperature, dissolved with diethylpyrocar-
bonate-treated water, and stored at –80
oC. The quality and 
integrity of RNA were confirmed by agarose gel electro-
phoresis and ethidium bromide staining, followed by visual 
examination under ultraviolet light. The cDNA was then 
prepared from 1 μg of random priming by using a First-St-
rand cDNA Synthesis Kit (Amersham Biosciences Europe 
GmbH, Freiburg, Germany) according to the manufac-
turer’s protocol.
3. Real-time polymerase chain reaction
To quantify the expression levels of DBC1, real-time poly-
merase chain reaction (PCR) amplification was performed 
by using a Rotor Gene 6000 instrument (Corbett Research, 
Mortlake, Australia). Real-time PCR assays using SYBR 
Premix EX Taq (Takara Bio Inc., Otsu, Japan) were carried 
out in microreaction tubes (Corbett Research). For amplifi-
cation we used DBC1 (201 bp) sense (5’-CCC TCG CCC GCC 
TAC TAT-3’) and antisense (5’-GCT GGG CGG GGT TGT 
AGA-3’) primers. The PCR reaction was performed in a fi-
nal volume of 10 μL, consisting of 5 μL of 2× SYBR premix 
EX Taq buffer, 0.5 μL of each 5’- and 3’- primer (10 pmol/μL), 
and 1 μL of the sample cDNA. The product was purified 
with a QIAquick Extraction kit (QIAGEN, Hilden, Ger-
many), quantified with a spectrometer (MBA2000, Perkin 
Elmer, Fremont, CA, USA), and sequenced with an auto-
mated laser fluorescence sequencer (ABI PRISM 3100 
Genetic Analyzer, Applied Biosystems, Foster City, CA, 
USA). The known concentration of the product was 10-fold 
serially diluted from 100 pg/μL to 0.1 pg/μL. The dilution 
series of PCR products was used to establish a standard 
curve of real-time PCR. The real-time PCR conditions were 
1 cycle at 96
oC for 20 seconds, followed by 40 cycles of 3 sec-
onds at 96
oC for denaturation, 15 seconds at 60
oC for an-
nealing, and 15 seconds at 72
oC for extension. The melting 
program was performed at 72
oC–95
oC with a heating rate 
of 1
oC per 45 seconds. Spectral data were captured and ana-
lyzed by using Rotor-Gene Real-Time Analysis Software 
6.0 Build 14 (Corbett Research). All samples were run in 
triplicate. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was applied as an endogenous RNA reference 
gene. Gene expression was normalized to the expression of 
GAPDH.
4. Statistical analysis
Because the expression levels of DBC1 were highly skewed 
to the left, even after log transformation, we performed ei-
ther a Mann-Whitney U test or a Kruskal-Wallis test. Pati-
ents were classified as having a high expression of DBC1 
or a low expression of DBC1, with the median of the mRNA 
expression as the cutoff value. The Kaplan-Meier method 
was used to estimate the time to recurrence and pro-
gression, and differences were assessed by using log-rank 
statistics. The prognostic value of DBC1 expression was an-
alyzed by using a multivariate Cox proportional hazard re-
gression model. Statistical analysis was performed by using 
IBM SPSS ver. 20.0 (IBM Co., Armonk, NY, USA), and a 
p-value＜0.05 was considered statistically significant.
RESULTS
1. Baseline characteristics
Table 1 lists the baseline characteristics of the 34 control 
and 344 bladder cancer (220 NMIBC and 124 MIBC) pa-
tients included in the study. The mean age of the bladder 
cancer patients was 66.9 years (range, 24 to 87 years) and 
that of the controls was 53.9 years (range, 19 to 80 years). 
Of the 220 NMIBC patients, 73 (33.2%) experienced re-Korean J Urol 2013;54:631-637
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TABLE 2. mRNA expression levels of DBC1 in the control and 
bladder cancer patients
Group
mRNA expression level (×10
4 
copies per μg), median (IQR)
p-value
a
Control 
Bladder cancer
Control 
NMIBC
Control
MIBC
NMIBC
MIBC
17.49 (9.84–36.12)
24.42 (6.38–92.61)
17.49 (9.84–36.12)
36.55 (6.38–109.02)
17.49 (9.84–36.12)
17.32 (3.87–63.23)
36.55 (6.38–109.02)
17.32 (3.87–63.23)
0.414
0.128
0.642
0.010
IQR, interquartile range; NMIBC, nonmuscle invasive bladder 
cancer; MIBC, muscle invasive bladder cancer.
a:p-values were based on the Mann-Whitney U test.
TABLE 3. Multivariate Cox regression analysis for prediction of tumor recurrence, progression to MIBC
Variable
Tumor recurrence Progression to MIBC
HR (95% CI)
a p-value HR (95% CI)
a p-value
Age (＜67 yr vs. ≥67 yr)
Gender (male vs. female)
Tumor size (＜3 cm vs. ≥3 cm)
Tumor number (single vs. multiple)
DBC1 expression (high vs. low)
Grade 
    G1
    G2
    G3
T stage (Ta vs. T1)
Intravesical therapy (No vs. Yes)
0.949 (0.585–1.540)
1.381 (0.767–2.488)
1.271 (0.770–2.100)
1.153 (0.706–1.883)
1.115 (0.674–1.842)
1
b
1.244 (0.610–2.539)
1.969 (0.815–4.754)
1.535 (0.805–2.926)
0.220 (0.118–0.411)
0.834
0.282
0.348
0.569
0.672
-
0.548
0.132
0.193
＜0.001
1.325 (0.496–3.545)
0.394 (0.088–1.767)
4.402 (1.286–15.074)
0.818 (0.286–2.341)
7.104 (1.516–33.293)
1
b
3.261 (0.309–34.455)
18.693 (1.594–219.266)
3.872 (0.701–21.381)
0.258 (0.075–0.893)
0.575
0.224
0.018
0.708
0.013
-
0.326
0.020
0.120
0.032
MIBC, muscle invasive bladder cancer; HR, hazard ratio; CI, confidence interval.
a:Multivariate Cox regression analysis was used to estimate HR with the corresponding 95% CI. 
b:Reference.
currence and 22 (10.0%) experienced progression. Four pa-
tients with Ta progressed into T1, and the other 18 patients 
progressed into muscle-invasive disease. Intravesical 
therapy was performed in 111 patients (50.5%) after TUR; 
74 patients were treated with BCG and 37 with mitomycin 
C. The mean intervals for recurrence and progression were 
20.7 months (range, 6.4 to 133.6 months) and 43.0 months 
(range, 6.6 to 115.4 months), respectively. During fol-
low-up, 14 of 220 patients (6.4%) with NMIBC died of blad-
der tumors, and the mean interval for cancer-specific sur-
vival was 49.5 months (median, 40.5 months; range, 7.4 to 
115.4 months). 
Of the 124 MIBC patients, 70 cases (56.5%) underwent 
radical cystectomy and 57 patients (46.0%) received ad-
juvant chemotherapy. During follow-up, 60 of 124 patients 
(48.4%) with MIBC experienced progression and 50 
(40.7%) died of bladder cancer.
2. mRNA expression levels of DBC1 in normal and cancer 
tissue
To identify whether DBC1 is involved in bladder carcino-
genesis, the mRNA expression level of DBC1 was analyzed. 
DBC1 levels did not differ between normal mucosa and 
bladder cancer tissue, between normal mucosa and 
NMIBC, or between normal mucosa and MIBC. However, 
DBC1 levels were significantly lower in patients with 
MIBC than in those with NMIBC (Table 1) (p=0.010).
3. Relationship between DBC1 mRNA expression levels 
and clinicopathologic features
The expression of DBC1 mRNA was significantly lower in 
cancer specimens from patients with a higher grade, T1 
stage, large size, and multiple tumors than in those with 
a lower grade, Ta stage, small size, and a single tumor in 
NMIBC (p＜0.001, p=0.002, p=0.013, and p=0.009, respec-
tively) (Table 2). However, DBC1 expression showed no sig-
nificant differences according to clinicopathological pa-
rameters such as tumor stage, grade, progression, and can-
cer-specific death in MIBC (data not shown).
4. Prognostic value of DBC1 mRNA expression levels for 
recurrence, progression, and survival in NMIBC
In the multivariate analysis, intravesical therapy (hazard 
ratio [HR], 0.220; p＜0.001) was the independent predictor 
of tumor recurrence. Tumor size (HR, 4.402; p=0.018), tu-
mor grade 3 (HR, 18.693; p=0.020), intravesical therapy 
(HR, 0.258; p=0.032), and DBC1 expression (HR, 7.104; 
p=0.032) were the independent predictors of progression 
to MIBC (Table 3). 
Analysis using Kaplan-Meier curves revealed prolonged 
recurrence, progression-free survival, and cancer-specific 
survival of high DBC1 expressors compared with low ex-
pressors in NMIBC (p=0.023, p=0.024, and p=0.036, re-
spectively) (Fig. 1A–C). 
DISCUSSION
In the present study, we investigated the contribution of 
DBC1 to an increased risk of bladder cancer and the useful-Korean J Urol 2013;54:631-637
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FIG. 1. The probability of (A) recurrence, (B) progression to 
muscle invasive bladder cancer, and (C) cancer specific 
survival according to DBC1 mRNA expression levels. Cutoff 
value was 35.5×10
4 copies per mg.
ness of DBC1 expression as a prognostic marker in bladder 
cancer. DBC1 was found to be closely associated with clin-
icopathologic features and cancer-related survival in pa-
tients with NMIBC. Moreover, the expression of DBC1 was 
an independent predictor of progression to MIBC in pa-
tients with NMIBC. Our results suggest that DBC1 is a use-
ful prognostic marker for NMIBC and might be an im-
portant tool for individualized prognosis of patients with 
NMIBC. 
Loss of heterozygosity on chromosome 9 is the most fre-
quently reported genetic event in urothelial carcinoma of 
the urinary bladder. Approximately 60% to 70% of bladder 
tumors have loss of heterozygosity at one or more loci on 
either arm of chromosome 9 and approximately 30% dis-
play loss of the entire chromosome. Deletion mapping with 
microsatellite markers suggests the existence of several 
putative tumor suppressor loci on chromosome 9, and dele-
tions at chromosome 9 have been found in tumors of various 
grades and stages [23]. DBC1 is located within chromo-
some 9 (9q32–33) and has been identified as a potential tu-
mor suppressor gene that is commonly hypermethylated 
or deleted in bladder cancer. The 5’ region of DBC1 contains 
a CpG island that is aberrantly hypermethylated in ap-
proximately 50% of bladder cancer cell lines and tumors, 
40% of oral squamous cell carcinomas, 80% of non-small- 
cell lung cancer cell lines, and a proportion of primary 
non-small-cell lung cancer [18-20]. In addition, the exoge-
nous expression of DBC1 protein in human bladder tumor 
cell lines is known to suppress proliferation, and DBC1- 
mediated growth inhibition is reportedly due to an increase 
in the number of cells in the G1 phase of the cell cycle, which 
suggests a role for DBC1 in cell cycle control [21,24]. At 
present, however, the exact mechanism of action and the 
pathways in bladder carcinogenesis are unknown; there-
fore, DBC1 has not yet been placed in a functional pathway. 
Our data have shown some similarities and differences 
compared with previous studies. The most striking result 
was that DBC1 expression was closely associated with clin-
icopathologic features such as tumor stage, grade, size, and 
multiplicity in patients with NMIBC. Moreover, indivi-
duals with low DBC1 expression appeared to have an in-
creased predisposition toward progression to muscle-in-
vasive cancer as well as a reduced rate of survival from 
NMIBC. Intriguingly, DBC1 expression was significantly 
decreased in patients with MIBC compared with those with 
NMIBC. Decreased DBC1 expression in MIBC supports 
the finding that individuals with low DBC1 expression ap-
pear to have an increased predisposition for progression to 
muscle-invasive cancer. This result was contrary to pre-
vious in vitro evidence. Habuchi et al. [18,25] reported that Korean J Urol 2013;54:631-637
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mRNA expression was absent in 5 of 10 (50%) bladder can-
cer cell lines, and 52% of bladder tumors demonstrated pat-
terns of abnormal hypermethylation without correlation to 
tumor grade or stage. The results of that study suggested 
that hypermethylation of the DBC1 region is one of the ear-
liest alterations in the development of urothelial carcino-
ma in the bladder and that there may be an age-related hy-
permethylation-based field defect in normal urothelium. 
Although DBC1 mRNA expression appears to be sup-
pressed by hypermethylation of the 5'-region in vivo, there 
was no clear relationship between the methylation level of 
DBC1 and its mRNA expression. Unfortunately, there is 
no clinical evidence as to whether inactivation of the DBC1 
tumor suppressor gene (loss of mRNA expression) influen-
ces genetic susceptibility and the prognosis of bladder 
cancer. We also found highly left-skewed expression levels 
of DBC1 in normal urothelium. Normal human urothelial 
cells showed a decrease in DBC1 mRNA expression when 
cultured, with increasing DBC1 expression as cells passed 
to senescence, which suggests that DBC1 may have a role 
in maintaining cells in a quiescent state [26]. This mecha-
nism might explain the highly left-skewed expression lev-
els of DBC1 in normal urothelium.
A possible limitation of the present study is that we did 
not evaluate the protein levels of DBC1, such as by Western 
blot or immunohistochemical staining. We think that fur-
ther protein study of DBC1 is needed to confirm its function 
as a more reliable prognostic marker. Second, the present 
study had a relatively small sample size, particularly for 
control cases, which lowered the statistical power. Thus, 
further research is needed to confirm the prognostic value 
of DBC1 as it relates to disease progression and recurrence 
in NMIBC patients. 
CONCLUSIONS
The expression of DBC1 is associated with tumor ag-
gressiveness in NMIBC. The results of the present study 
suggest that the DBC1 gene may be a useful prognostic 
marker for NMIBC. This result could be an important tool 
for individualized prognosis for patients with NMIBC. If 
indeed DBC1 has a critical role in the disease progression 
of NMIBC, it could be a potential target for use in the pre-
vention of disease progression, such as with BCG im-
munotherapy or intravesical chemotherapy, because tran-
scriptional silencing can be reversibly controlled by in-
hibitors of methylation.
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